Investigational Drug Information for PF-06650833
✉ Email this page to a colleague
What is the development status for investigational drug PF-06650833?
PF-06650833 is an investigational drug.
There have been 12 clinical trials for PF-06650833.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 27th 2020.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and COVID-19. The leading clinical trial sponsors are Pfizer, Yale University, and Giovanni Franchin, M.D, Ph.D.
There are five US patents protecting this investigational drug and seventy-five international patents.
Summary for PF-06650833
| US Patents | 5 |
| International Patents | 75 |
| US Patent Applications | 21 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 2 (2020-11-27) |
| Vendors | 34 |
Recent Clinical Trials for PF-06650833
| Title | Sponsor | Phase |
|---|---|---|
| A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC) | Pfizer | Phase 1 |
| IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. | Pfizer | Phase 2 |
| IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation. | Giovanni Franchin, M.D, Ph.D | Phase 2 |
Clinical Trial Summary for PF-06650833
Top disease conditions for PF-06650833
Top clinical trial sponsors for PF-06650833
US Patents for PF-06650833
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06650833 | ⤷ Sign Up | Bicyclic-fused heteroaryl or aryl compounds | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-06650833 | ⤷ Sign Up | Bicyclic-fused heteroaryl or aryl compounds | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-06650833 | ⤷ Sign Up | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (Cambridge, MA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06650833
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06650833 | Argentina | AR099955 | 2034-04-04 | ⤷ Sign Up |
| PF-06650833 | Australia | AU2015242291 | 2034-04-04 | ⤷ Sign Up |
| PF-06650833 | Canada | CA2944475 | 2034-04-04 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
